Aulis Capital Closes Inaugural $200M Healthcare Fund

Aulis Capital is giving its healthcare investment strategy a $200M institutional base. The firm, led by Founding Managing Partner Nisa Leung, confirmed the final close of Aulis Capital Fund I, L.P. in November 2026, with the capital committed to an inaugural vehicle focused on early- and growth-stage life sciences and healthcare companies.

The investment proposition reaches across borders as well as stages of development. Aulis describes a role connecting global-minded companies with Asia's engineering and clinical capabilities, a mandate that puts the practical organization of healthcare innovation alongside the selection of promising science. For founders, the useful question is how that combination changes the people, partnerships and development decisions available to a company as it grows.

A final close gives Aulis a defined fund

The official Fund I announcement identifies US$200M in total capital commitments and explicitly describes a successful final closing. That establishes both the currency and the fundraising state. It leaves the amount already invested, the remaining investment capacity and the identities of limited partners undisclosed.

The manager and its investment vehicle also deserve separate identities. Aulis Capital is the firm making and supporting investment decisions; Aulis Capital Fund I, L.P. is the inaugural fund named in the announcement. Treating those names carefully keeps a fundraise from being mistaken for equity financing in a healthcare operating company.

There is a regulatory history behind the vehicle. A Form D signed in December 2025 identifies the Cayman Islands partnership, gives a Kowloon Bay, Hong Kong address and records Nisa Leung's relationship to its general-partner structure. The later firm announcement establishes the final close; the older filing documents an earlier point in the fund's formation and offering history.

That sequence matters when reading the number. Commitments give an investment manager a basis for future investment decisions, while the timing and composition of those decisions depend on the vehicle's actual activity. Aulis has announced the completed fundraise without publishing a geography-by-geography spending plan or a schedule of checks.

Nisa Leung brings healthcare experience into a new firm

Nisa Leung's biography at ARDD 2026 identifies her as Aulis's Founding Managing Partner and describes her earlier work establishing and leading Qiming Venture Partners' healthcare practice from 2006. That background supplies context for the new manager without transferring every investment from a previous employer into Aulis's portfolio.

BioCentury's November 5 coverage corroborates the $200M close and reports offices in Hong Kong and California. It also identifies former McKinsey partner Franck Le Deu as a Venture Partner at Aulis. Together, the scientific and company-development dimensions of the team's work help explain the kind of support the manager is positioning around its capital.

The firm's published approach spans medical devices, diagnostics and digital health, alongside its broader healthcare focus. It emphasizes strategic partnerships and access to engineering and clinical development resources in Asia. Those are stated investment capabilities and priorities, rather than evidence of a particular return or clinical outcome.

For a founder considering such an investor, the mandate creates a more detailed conversation than geography alone can provide. Which clinical collaborators fit the programme? What expertise does the company need internally? Where can an external relationship move the development work forward? A cross-border investor becomes useful through the quality of those answers inside a particular company, where the scientific plan and the organization carrying it out have to develop together.

EpiBiologics puts a portfolio relationship in view

EpiBiologics provides a concrete record of Aulis's investment activity before the final fund close. In its January 8, 2026 financing announcement, the biotech named Aulis among the new investors in a $107M Series B and named Nisa Leung as an incoming board observer. The release describes that specific financing at that point in time; it does not establish how much Aulis invested or identify the subscribing Aulis vehicle.

The company's development programme also makes the international work tangible. EpiBiologics reported its first patient dosed with EPI-326 on April 19, 2026. The announcement described a Phase 1 study of its tissue-selective EGFR-degrading antibody, with enrollment in the US and planned Asia-Pacific sites, including South Korea.

That clinical milestone is evidence of a programme moving into human study, with safety, tolerability and preliminary activity among the questions the trial was designed to examine. It gives the investment story an operating setting while leaving the medicine's eventual clinical and commercial outcome open.

A founder comparing financing options can use that distinction to ask about the investor's actual role. Board observation, development advice and introductions carry different responsibilities, and a fund's announced size cannot settle which of them a particular team will receive. The value of the Aulis relationship will be defined within the companies choosing to work with it, through the specific scientific and organizational decisions they face.

For Aulis, the final close now sits alongside relationships in which scientific development is already underway. As founders work through clinical partnerships and the evidence their programmes need, Nisa Leung's new firm has a defined pool of commitments behind the mandate it is asking those companies to consider.